一个拟议的算法用于药理治疗老年患者普遍焦虑症的药理治疗
Anderson Chen1, Eran Metzger2, Soyoung Lee3
1Psychiatry Department, Massachusetts General Hospital, Boston, MA, USA.
Journal of geriatric psychiatry and neurology
|October 1, 2024
概括
这个算法指导了老年人普遍焦虑障碍 (GAD) 的治疗. 第一线选择包括SSRI,为特定需求提供替代品,并在随后的试验中进行不充分的反应.
科学领域:
- 心理药理学 心理药理学
- 老年精神病学是一门精神病学专业.
- 焦虑症 焦虑症 焦虑症
背景情况:
- 在老年人中治疗泛性焦虑障碍 (GAD) 的新治疗算法.
- 由哈佛大学南岸计划的精神药理学算法项目开发.
- 基于对相关医学文献的全面审查.
研究的目的:
- 为老年人群中GAD的药物治疗提供基于证据的指导.
- 概述药物选择和增强的逐步方法.
- 为解决特定考虑因素,如副作用概况和同时存在的条件.
主要方法:
- 对老年GAD药物治疗现有研究的系统审查和综合.
- 基于疗效和安全数据开发一个序列治疗算法.
- 考虑一线,二线和三线治疗选择.
主要成果:
- 选择性血红素再吸收抑制剂 (SSRI),特别是塞特拉林或埃斯基塔洛普拉姆,被推作为一线治疗.
- 布斯皮龙是老年人优先避免性副作用的替代品.
- 二线选择包括不同的SSRI或氨酸-上腺素再吸收抑制剂 (SNRIs),如文拉法辛或杜洛西丁.
- 第三线选择包括普雷加巴林/加巴丁,衣草油和阿戈梅拉丁,在耐火病例中考虑使用奎蒂亚平.
- 建议在急性治疗中谨慎使用二和氧.
- 其他药物,如维拉佐,,米尔塔扎和大麻,有支持证据,但优先级较低.
- 这些指导方针涉及在仔细监测下继续使用先前存在的二二类药物治疗.
结论:
- 该算法提供了一种结构化的方法来管理老年GAD,优先考虑安全性和有效性.
- SSRI和SNRI构成了治疗的支柱,对不响应者有增强策略.
- 仔细考虑药物风险和益处至关重要,特别是在长期治疗中,如二zepines.
相关概念视频
01:26Anxiolytic Drugs: Overview
238
Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
238
01:29Anxiolytic Drugs: Benzodiazepines and Buspirone
563
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
563
01:30Generalized Anxiety Disorder
67
Generalized Anxiety Disorder (GAD) is a chronic condition characterized by excessive and uncontrollable worry that persists for at least six months, significantly interfering with daily functioning. Unlike situational anxiety, which arises in response to specific stressors, GAD often occurs without a clear cause. Individuals may experience disproportionate worry about work, health, or relationships. For instance, a person might continuously fear poor health despite normal medical evaluations or...
67
01:22Behavior Therapy
43
Behavior therapy incorporates diverse techniques rooted in classical conditioning principles to address maladaptive behaviors and anxiety disorders. These methods aim to reduce avoidance behaviors, foster adaptive coping mechanisms, and alter associations between stimuli and responses, making them effective in a wide range of therapeutic contexts.
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
43
01:28Drug Therapy
39
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
39
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170